develop commerci
readout upcom -- initi coverag buy
aslan clinical-stag singapore-bas biopharmaceut compani
oncolog therapeut aslan signific asset varlitinib
promis oral revers pan-her inhibitor target human
epiderm growth factor receptor caus uncontrol growth
pan-her inhibit varlitinib multipl late-stag clinic trial
tumor increas activ includ biliari tract
gastric stomach cancer also much higher preval
asia aslan center manag materi asian drug
develop commerci experi aslan drive bulk
varlitinib clinic develop asia effici measur
aid develop still preserv potenti orphan
approv major market world-wide
upcom biliari tract cancer china us
phase data gastric cancer varlitinib could launch
estim global peak revenu indic separ
oral dhodh inhibitor mid-stag develop aml
appear materi promis larg subset aml patient
phase data readout signific prospect varlitinib
launch coverag aslan asln buy price target
varlitinib materi potenti biliari tract tumor
her-driven activ current line therapi dismal aslan
singl arm studi read china random studi
treetopp us expect posit gastric
cancer aslan enrich co-express
gastric cancer earli readout expect
fully-tax npv approach aslan collect valu
approxim support price target
valu varlitinib global consider biliari tract cancer
gastric cancer use aml cash
asset repres differ
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
pharmaceut singapore-bas cayman island incorpor
biopharmaceut compani approxim employe
engag develop commerci innov oncolog
therapeut aslan signific asset varlitinib promis oral
revers novel pan-her inhibitor target human epiderm growth
receptor caus excess prolif activ
uncontrol cellular growth varlitinib current multipl clinic trial
multipl tumor increas activ broad-bas
signal inhibit aslan seek demonstr varlitinib activ
set
exhibit aslan drug develop pipelin varlitinib
mani tumor includ biliari tract gastric stomach cancer
other wide preval asian countri aslan materi
oper experi aslan therefor look region
varlitinib rapid effici clinic trial enrol develop still
retain potenti approv major market world-wide
trial includ potenti singl pivot studi
condit differ geograph region sever import
near-term data readout exhibit believ varlitinib activ
differenti small molecul pan-her inhibitor result materi
billion peak global revenu potenti collect across number
her-posit tumor type varlitinib meaning potenti gastric
biliari tract potenti cancer addit molecul
increment ad especi initi coverag asln
adss buy price target
aslan addit asset appear promis aslan two addit
promis asset well partner program
develop along develop partnership focus
inhibit modybodi novel antibodi fragment
technolog promis novel dhodh inhibitor phase
develop aml data releas could materi
potenti aml solid tumor type dhodh may relev
tripl neg breast cancer tnbc hepatocellular carcinoma
earli stage
develop aslan look establish proof-of-concept sever
atop dermat asthma prior outlicens molecul expect
program could also add materi valu aslan oper
time
novel
blackwel et al pan-erbb inhibit superior select erbb inhibit
preclin model signal multipl erbb receptor american associ cancer research
chemic biolog aspect inflamm cancer
varlitinib differenti potenti advantag broad inhibit
demonstr select chart exhibit varlitinib could
advantag select inhibitor due broad-bas
inhibit famili also known erbb compris four
receptor tyrosin kinas includ egfr
signal member famili complex involv
wide rang activ hetero- homodim among famili member
key signal pathway util mani tumor co-express
shown involv resist mechan select egfr
inhibitor amplif and/or over-express associ
increas risk metastasi wors outcom tumor signal
sever famili member potenti sensit pan-
inhibitor compar select inhibitor sever tumor type
signal multipl famili member includ gastric hepatobiliari
pancreat ovarian therefor potenti respons
type pan-her inhibitor varlitinib origin
novel oral revers inhibitor target member erbb famili
either directli indirectli earli studi
varlitinib shown encourag clinic activ sever tumor type
includ gastric stomach biliari tract metastat breast
cancer along manag toxicity/toler profil like due part
revers inhibit
 highli select her-famili inhibit kinas
 encourag earli phase activ her-rel tumor
 potenti enrich trial design her-driven tumor
 potenti singl pivot studi gastric biliari tract tumor
 possibl use breast cancer her-driven tumor
cancer develop varlitinib demonstr encourag
respons early-phas clinic studi her-rel cancer
notabl varlitinib demonstr solid efficaci phase
combin variou chemotherapi show overal respons rate
gastric tumor biliari tract tumor
pretreat patient exhibit encourag result hand
aslan embark multipl potenti pivot studi
varlitinib biliari gastric tumor gastric stomach tumor aslan
enrich popul co-express popul
estim gastric cancer approxim biliari tract
cancer express her-famili receptor accord aslan
geographi shortli biliari tract gastric stomach cancer other
wide preval asian countri aslan materi oper
experi exhibit aslan therefor look region drive
varlitinib rapid effici clinic trial enrol develop still
retain potenti approv major market world-wide varlitinib
current trial includ potenti singl pivot studi
condit differ geograph region sever
exhibit varlitinib relev cancer preval asia/pacif vs us
benefici twist us china commerci presenc plan aslan
focus develop oncolog therapeut though oper
understand cancer preval asia provid aslan
potenti effici drug develop import consider
aslan manag experi region led ceo carl firth
execut team year drug develop commerci
experi asia compani plan leverag broad experi
asia deep local relationship expedit drug develop
commerci effort use clinic data approv geographi
diseas consid orphan us eu materi
previou commerci experi asia china specif aslan plan
begin build target commerci organ china asian
market anticip potenti regulatori approv
varlitinib biliari tract gastric cancer plan similar target
commerci effort varlitinib us well
broadli activ pan-her inhibitor believ varlitinib potenti
materi consid line biliari tract cancer sever market
global gastric cancer market current treatment
leav room addit therapeut option believ varlitinib
potenti world-wide peak revenu exceed billion indic
addit potenti breast colorect cancer given broad-
base inhibit though yet includ estim
aslan asln valuat aslan oper potenti
signific revenu earn variabl come quarter
year result valu oper use fully-tax risk-weight
net present valu methodolog major asset calcul npv
estim use asln us adss million repres five
ordinari share approxim million ordinari share outstand
aslan advanc proprietari asset varlitinib biliari tract cancer
posit gastric cancer potenti other repres
bulk valu aslan oper view despit varlitinib
current progress pivot studi continu
activ oncolog sector biotechnolog valu asln adss
aslan oper independ though assumpt could
certainli chang meaning clinic progress varlitinib
assum aslan oper independ assess total valu
aslan lead program asset per asln exhibit
assum aslan continu oper independ
tyrosin kinas inhibitor current enrol sever potenti
pivot studi aslan valuabl asset believ varlitinib
materi potenti therapeut line therapi potenti earlier
treatment biliari tract cancer line set co-
express advanc gastric cancer addit due activ
manag toler believ may potenti certain colorect
breast cancer collect assum broad use biliari gastric
cancer estim peak revenu billion global varlitinib
exhibit aslan control commerci right us
china licens right eu possibl japan
develop partner use tumor beyond current
repres upsid estim intellectu properti protect
anticip extend least varlitinib estim valu
asset aslan per asln exhibit
aslan asset consider aslan
two addit promis asset novel dhodh inhibitor
aml novel inhibitor inflammatori
condit molecul earli stage develop
potenti add materi valu time earli
develop valu collect along partner
per asln aslan net cash estim
million per asln includ cash recent us ipo
nol asset drag gener corpor oper expens
total per asln share yield total aslan asset share
count figur includ current outstand amount million
ordinari share post ipo repres million us adss sinc one
aslan revenu estim aslan expect gener
meaning product sale revenu us approv varlitinib biliari
tract cancer though potenti approv china
intern licens fee mileston may gener revenu
near-term clinic trial result
assum fda approv estim us drug sale revenu
million physician becom familiar molecul varlitinib us
china-rel revenu retain book aslan
estim grow million million
mileston potenti intern royalti also ad modestli
overal aslan compani revenu year given differenti
estim varlitinib could reach global peak billion revenu
post aslan book varlitinib revenu million relat
us china
aslan earn estim aslan made materi expenditur
primari molecul varlitinib expect spend increas
post net loss million increas materi
million aslan move aggress
global pivot
develop biliari tract cancer primari asset well
gastric cancer clinic program estim aslan lose million
varlitinib progress potenti pivot trial expand
gastric cancer program assum data posit
modest pre-launch expens partli off-set expect mileston aslan
potenti report modest net loss million year
launch expens larg off-set revenu addit
estim mileston intern partner aslan estim post
modest loss million varlitinib growth estim profit
increas materi year life varlitinib asset
approach patent expir post
aslan sinc aslan biotechnolog compani
revenu primari asset pivot studi except capit
rais aslan oper cash flow larg track earn loss
term capit rais aslan execut us ipo million may
previous list taipei stock exchang rais million
support continu develop varlitinib earlier rais
gross proce million multipl privat financ transact
flow like earn expect bolster up-front payment
mileston licens varlitinib begin like addit
capit rais possibl even like licens partner abl
secur intern market though expect prior
addit meaning clinic result molecul clinic data
potenti addit capit rais
estim million project launch varlitinib
provid compani enough profit contribut materi aslan
cash posit begin onward estim aslan
cash flow larg mirror net incom chang except statement
could occur wake challeng data treetopp label
varlitinib materi competit expect
exhibit prior import event aslan
preclin profil initi describedarray present preclin enter clinicarray begin broad phase develop data cholangiocarcinoma patientsupport develop biliari tract found ceo dr carl firthgoal leverag asia drug-develop licens varlitinib arrayiniti agreement develop clinic licens almiralliniti agreement develop rheumatoid pair biopsi gastric cancer datavarlitinib posit impact downstream signal rais seri bfund use advanc licens cslwill partner clinic poc econom initi line biliari cancerenrol biliari tract cancer deal almirallaslan control global commerci right rais seri cfund use advanc activ gastric pdx model aacranti-tumor activ signal inhibit support publish cell support amldhodh inhibit enabl differenti aml rais pre-ipo roundfund use advanc rais list taipei exchangelist oversubscrib ticker phase solid tumor data orr patient includ cholangiocarcinoma induc differenti preclin amlwork conduct w/ nci support move treetopp studi enrol patientposit data support us approv line biliari trial line gastric cancer expans data support us breast cancer data esmo asiavarlitinib activ line aml launchesreceiv ind singaporevvvjan varlitinib dealaslan control global commerci right varlitinibvvvvjan registr strategi chinapotenti approv biliari cancer orrvvvvapril activ hccpreclin data support investigator-initi trialvvvmay us ipo rais advanc varlitinib key datavvvv signific least import vvvvv import
varlitinib preclin activ present multipl congress
varlitinib oral activ inhibitor egfr revers atp-
competit inhibitor dose-rel tumor growth inhibit observ
overexpress tumor model also achiev tumor regress lung
breast cancer vivo model bid well toler
per day day
biopharma launch phase dose-escal studi evalu varlitinib
toler pk profil hint efficaci patient advanc cancer
varlitinib initi phase data present multipl congress
develop expand data present aacr-nci-eortc
meet dr mace rothenberg ingram professor cancer research
vanderbilt-ingram cancer center show varlitinib well toler
bid typic tki fatigu nausea anorexia diarrhea rash
vomit drug concentr dose-depend achiev level
continu profound system inhibit patient
complet cohort bid stabl diseas bid regimen
chosen develop array expand trial enrol
addit patient onto phase herceptin-resist
breast family-driven cancer
varlitinib demonstr activ vs lapatinib
tumor growth inhibit compar lapatinib vivo xenograft model
co-express gastric cancer overexpress nsclc
cancer patient confirm co-express tend
greatest clinic benefit separ varlitinib bid achiev
regress target lesion patient cholangiocarcinoma subset
biliari tract cancer accompani tumor marker respons patient
ovarian patient cervic cancer patient stabl diseas
varlitinib use chemo combin array initi phase
program assess varlitinib combin capecitabin docetaxel
gemcitabin advanc metastat solid tumor data vivo
preclin tumor model express co-express
show low dose varlitinib increas anti-tumor activ trastuzumab
varlitinib chemistri summari phase data
present describ chemistri synthesi varlitinib ration
famili inhibitor approach summar varlitinib phase safeti
data set patient treat varlitinib monotherapi
chemo combin date monotherapi bid dlt
grade anorexia grade ast/alt elev varlitinib chemo agent
pk profil affect combin
aslan licens varlitinib array initi agreement
array aslan agre global develop varlitinib proof concept
initi target gastric cancer asia-bas develop program
posit proof concept aslan identifi partner
conduct phase develop commerci varlitinib up-front
payment made parti would split futur econom
phase partner prior
licens asset varlitinib
monotherapi chemotherapi combin evalu
patient agreement amend januari provid
aslan global commerci right varlitinib
aslan partner bristol myer squibb
partner enter innov agreement leverag aslan asia-bas
drug develop expertis acceler develop
clinic proof concept gastric lung cancer aslan obtain exclus
commerci right china australia korea taiwan asian market
deal structur also provid bristol rate option recal
aslan licens almiral initi
agreement aslan receiv global right develop almiral dhodh
inhibitor formerli rheumatoid arthriti aslan
agre fund advanc rheumatoid arthriti
end phase asia-pacif develop program look partner
phase develop commerci time
licens single-dos shown well toler healthi
volunt agreement subsequ amend provid aslan
global commerci right
phase mad studi begin singapor singapor
health scienc author approv clinic trial applic evalu
multipl ascend dose phase studi assess safeti
toler pk
varlitinib top-line data gastric cancer pair biopsi studi
phase pair biopsi trial conduct seoul nation univers hospit
enrol patient refractori recurr metastat gastric carcinoma
amplifi tumor tumor co-express egfr
tumor biopsi taken therapi analyz
downregul key signal pathway data present
octob primarili fund clinic develop varlitinib gastric cancer
fund rais led cenova ventur includ morningsid group
xinchen new investor exist investor bioveda capit
day
aslan establish presenc taiwan aslan open offic
taipei februari manag local clinic manufactur activ
develop limit asx rate receptor-alpha subunit
antibodi inhibit signal asthma
clinic proof concept primarili site asia partner
program phase commerci activ assess
patient moder persist sever allerg asthma refractori
exist therapi atop dermat
varlitinib safeti studi launch taiwan aslan dose first
patient safeti studi taiwan explor safeti toler
varlitinib combin chemotherapi doublet cisplatin/fu
cisplatin/capecitabin treatment advanc solid tumor includ
varlitinib esmo phase pair biopsi data advanc
gastric cancer varlitinib monotherapi bid day led
biolog activ co-express amplifi gastric cancer
evalu pharmacodynam data set co-express
reduct pmapk activ cell prolifer regul
cellular marker prolifer upregul tunel
measur cell apoptosi activ reduct pakt signal
phase solid tumor patient posit patient
solid tumor success dose-escal treat least
day qd bid regimen dual cmet ron inhibitor
safe well toler dose evalu achiev long-term
stabl diseas partial respons certain tumor type addit
potent inhibit plasma biomark ron activ
collabor explor genom background varlitinib hyper
respond understand gastrointestin cancer aslan partner
act genom explor genom signatur patient
achiev outsiz respons varlitinib also enter memorandum
understand nation cancer centr singapor ncc enhanc
studi new therapeut common form gastrointestin cancer
preval asia gastric cancer hepatocellular carcinoma liver
cholangiocarcinoma memorandum provid collabor project
explor preclin research jointli conduct clinic trial diseas
symposium asia
varlitinib grant orphan drug design fda
cholangiocarcinoma subset biliari tract cancer orphan
design qualifi aslan develop incent provid
period market exclus protect gener entri
clearanc initi varlitinib phase cholangiocarcinoma
aslan receiv clearanc ind equival
singapor taiwan evalu varlitinib
patient
varlitinib licens hyundai pharmaceut south korea
aslan licens varlitinib develop commerci right hyundai
rate treatment cholangiocarcinoma south
korea aslan elig receiv undisclos regulatori commerci
mileston royalti product sale
revis deal almiral give aslan control
part revis agreement aslan receiv global right develop
commerci oncolog use exclud topic
dermatolog indic aslan pay almiral million
develop million regulatori mileston tier mid-single-
digit royalti aslan licens technolog pay almiral sublicens
fee
close januari primarili fund develop varlitinib
expand applic fundrais includ new investor
pharmaceut haitong
morningsid bioveda cenova sagamor
varlitinib data gastric cancer model single-ag
gastric cancer patient-deriv
xenograft scid mice over-express protein activ
dose-depend tumor stasi observ bid regress
achiev bid varlitinib shown inhibit multipl cell
prolifer surviv pathway mapk other data correl
well phase pair biopsi trial support on-going phase
aslan open offic china aslan open shanghai offic
april manag local clinic manufactur activ
varlitinib data hepatocellular carcinoma model
single-ag varlitinib activ pdx model co-
express complet tumor regress achiev bid
drug well toler dose analysi suggest varlitinib
stop cell prolifer drove apoptosi
varlitinib grant fda orphan drug design gastric cancer
orphan design qualifi aslan develop incent
provid period market exclus protect gener entri
exist
aslan rais million aslan rais million pre-ipo
fund primarili advanc develop varlitinib pipelin
fund toptaiwan kgi vc ta ya ventur well intern
institut fund mileston capit daiwa taiwan-japan biotech fund
reacquir bristol-my august bristol reacquir
right china australia korea taiwan asian
market aslan receiv million up-front elig
million pre-commerci mileston royalti global sale
transact valid aslan strategi rapidli attain high-qual
clinic leverag asian drug develop expertis
aslan gain global right ron antibodi
aslan licens global right develop commerci novel io
antibodi target recepteur dorigin nantai ron singapor
agenc scienc technolog research aslan respons
design clinic develop program complet
preclin develop
paper publish cell identifi dhodh target
aml syke et al identifi dhodh potenti key target aml drug
develop inhibit dhodh enzym shown enabl myeloid
differenti human mous aml cell deplet function
leukemia-initi cell addit dhodh inhibit may broad
util across aml subtyp
aslan gain option preclin modybodi technolog
aslan enter research collabor licens agreement
nanyang technolog univers singapor ntu develop modybodi
target aslan exclus option obtain global right
program modybodi novel stabil heavi chain monoclon
penetr due small size customiz natur pk
encourag top-lin phase data varlitinib breast cancer
varlitinib plu capecitabin compar tykerb lapatinib plu
capecitabin second-lin therapi breast cancer patient
progress herceptin trastuzumab among patient therapi
least month tumor shrinkag week significantli greater
subset orr vs varlitinib lapatinib
respect differ observ os
aslan enter research collabor singapor
aslan collabor cancer scienc institut singapor csi
technolog potenti advantag
nation univers cancer institut singapor nci evalu
mono combin therapi hematolog malign
enrol begin phase trial varlitinib biliari tract
cancer japan februari aslan enrol first patient onto phase
trial varlitinib solid tumor biliari tract cancer japan trial
enrol patient assess safeti toler varlitinib
monotherapi combin capecitabin success complet
trial support enrol japanes patient onto global biliari tract
aslan list taipei stock exchang june aslan
ordinari share list taipei stock exchang tpex
code list time oversubscrib rais million
total
varlitinib encourag earli phase solid tumor data
patient advanc solid tumor receiv escal dose varlitinib
either cisplatin/capecitabin cycl
varlitinib monotherapi patient evalu respons includ
pr stabl diseas progress
respons cholangiocarcinoma deep durabl includ patient
reduct liver tumor size cycl cr liver lesion
cycl anoth patient measur lesion liver biliari
tract achiev long-term diseas control month diarrhea
occur grade higher case control
standard loperamid imodium
preclin data support use aml
shown induc differenti aml blast cell line preclin studi
conduct collabor cancer scienc institut
singapor nation univers cancer
induct aml blast cell differenti associ apoptosi ie cell
death normal aml bone marrow data
support move phase develop relapsed/refractori aml
varlitinib bid dose identifi combin
cisplatin/capecitabin
june global pivot treetopp studi biliari tract cancer enrol
first patient first patient enrol onto global pivot treetopp
studi design support acceler approv fda studi enrol
biliari tract cancer patient fail line treatment receiv
varlitinib plu capecitabin capecitabin site globallyth trial
led dr milind javl md anderson cancer center base
discuss fda minimum patient need enrol
us site support us approv co-primari endpoint orr
top-line data expect
patient aslan enrol first patient onto phase program
varlitinib plu folfox vs folfox first line treatment advanc
metastat gastric cancer co-express phase portion
enrol patient site asia europ assess primari endpoint
chang target tumor size week phase data expect
posit one-sid aslan enrol phase program
addit patient assess primari endpoint overal surviv
varlitinib clinic develop begin partner nation
univers cancer institut singapor nci initi first clinic trial
varlitinib patient advanc metastat hepatocellular carcinoma
phase trial evalu enrol expans
cohort patient diseas progress line therapi
sorafenib trial assess safeti efficaci predict biomark
analysi aslan contribut varlitinib partial fund
varlitinib phase breast cancer data esmo asia patient
metastat breast cancer fail trastuzumab random
capecitabin plu bid varlitinib daili lapatinib
primari endpoint percentag chang tumor reduct
week tumor size reduct numer greater varlitinib vs
orr similar vs patient remain
studi day sensit analysi demonstr statist
signific higher reduct tumor size varlitinib vs
one-sid numer superior orr vs
common ae diarrhea varlitinib arm diarrhea
palmar-plantar erythrodysaesthesia syndrom occur
lapatinib arm intend exposur percentag intend dose
lower varlitinib
ind approv singapor kickoff phase aml
phase studi initi enrol relapsed/refractori aml patient
site singapor australia assess
monotherapi dose day
progress primari endpoint rate complet remiss
complet remiss incomplet bone marrow recoveri expans
cohort enrol addit patient potenti combin
jan revis array deal give aslan control varlitinib part
revis agreement aslan paid array up-front fee million array
also entitl receiv addit payment million within
month mileston tier low double-digit royalti
base net sale varlitinib addit aslan also expect pay
array fee payment receiv sublicens varlitinib
right undisclos amount
jan favor regulatori pathway china announc follow
discuss chines fda cfda posit aslan expect file
approv biliari tract cancer base orr single-arm
pivot trial data avail late
april varlitinib preclin hepatocellular carcinoma data
studi conduct collabor nation cancer centr
singapor ncc design demonstr varlitinib activ
patient-deriv xenograft pdx model studi molecular mechan
varlitinib tumor suppress anti-angiogen potenti varlitinib
demonstr tumor regress vessel normal erbb-depend
mutat beta-catenin hepatocellular carcinoma patient-deriv xenograft
may aslan rais million us ipo aslan list american
depositori share adss nasdaq global market rais million
million net sale million adss fund
develop varlitinib equal ordinari share list
exhibit potenti upcom catalyst aslan
phase
june new varlitinib phase data aslan present new
evalu varlitinib
carboplatin/paclitaxel /- trastuzumab advanc solid tumor varlitinib
bid day on/off combin paclitaxel identifi
recommend dose addit trastuzumab determin
safe poster abstract titl dose find studi varlitinib
trastuzumab carboplatin/paclitaxel advanc solid tumor
present morn poster session monday june addit
aslan present detail overview pivot treetopp studi
abstract sunday june morn
advanc clinic ind plan
initi phase develop fulli human monoclon
dateeventcommentsignificancejun ascobuild treetopp awar new chemo combo ind asthma allerg dermatitisclin advanc enabl line gastric cancer datatumor reduct support expans phase interim data amlposit dose-find move expans cohort interim line biliari cancer datafind support expans phase china line biliari cancer datapotenti acceler approv orr singl arm treetopp readout line biliari cancerorr support commerci partnership eu japanaslan maintain control us china marketsvvvv signific least import vvvvv import
antibodi specif bind inhibit activ
treatment asthma atop dermat asset licens
reach proof concept current plan call out-licens
phase commerci activ
data phase portion measur folfox without
varlitinib patient co-express elev
express inelig herceptin could support expans
global phase trial could potenti use support fda approv
posit outcom base tumor reduct week base one-
side p-valu signific phase studi expect enrol
addit patient evalu os primari endpoint
interim phase data aml interim data dose-
rang monotherapi portion aml patient could support move
expand patient cohort allow dhodh inhibitor
combin standard induct chemotherapi progress
primari endpoint rate complet remiss complet remiss
incomplet bone marrow recoveri data could provid basi
discuss potenti pathway acceler approv fda dhodh
inhibit promis biolog myeloid cell differenti
varlitinib interim phase data line biliari tract cancer
evalu varlitinib plu gemcitabine/cisplatin vs
gemcitabine/cisplatin alon line set dose-escal phase
portion determin provid basi expans
plan phase placebo-control studi patient per arm assess
primari endpoint posit aslan would enrol patient phase
late varlitinib chines studi pivot data line biliari tract
cancer follow discuss chines fda trial posit aslan
expect file approv base orr data single-arm trial
patient progress prior
chemotherapi varlitinib need statist exceed orr
order consid success secondari endpoint studi includ
os
possibl licens varlitinib region right aslan recent
fund million april expect fund expens surround
varlitinib pivot treetopp studi biliari tract cancer phase
develop gastric cancer aslan global right varlitinib though
believ compani licens molecul eu japan would
expect discuss heat late-stag pivot clinic data emerg
varlitinib global pivot treetopp result line biliari tract
cancer random double-blind placebo-control trial enrol
patient global site evalu varlitinib plu capecitabin vs
capecitabin alon co-primari endpoint orr
statist analysi plan allow primari success either endpoint
signific one-sid level endpoint signific
one-sid level either co-primari endpoint posit
aslan plan file acceler approv us base review
clinicaltri gov top-line data could announc earli
sinc aslan oncology-focus
compani modest infrastructur signific nich regard
asia drug develop expertis reason chanc larger
industri suitor could emerg find compani oper attract
time event alway challeng predict though
awar build varlitinib robust differenti pan-her clinic
profil given potenti program believ possibl
though estim modest potenti point yet
includ formal npv calcul
aslan focus develop oncolog therapeut though
materi benefici twist understand cancer preval
asia combin asia-bas develop platform provid
potenti compani develop drug effici could
achiev us eu major asian regulatori bodi japan
pharmaceut medic devic agenc pmda china food
drug administr cfda recent becom progress
approach toward drug develop exampl japan first approv
novel inhibitor opdivo nivolumab unresect melanoma
taiwan first approv gilotrif afatinib non-smal cell lung cancer
pmda introduc first acceler regulatori pathway sakigak
design state council china introduc seri
reform allow import drug approv use foreign data
dramat shorten approv timelin implement
addit recent data publish fda show asian countri
contribut global studi decad reach
level qualiti demand intern regul
exhibit asian preval cancer research led asian clinic
center asian investig
asia-bas clinic trial acceler develop addit
focus certain tumor type biliari tract gastric stomach cancer
other wide preval asian countri aslan
materi oper experi exhibit work lead
center asia exhibit recruit rate clinic trial
significantli increas nearli doubl rate us japan biliari
tract cancer two three time higher rate gastric cancer south
korea taiwan even cancer type preval higher
asian market particularli
patient asia may easili recruit due fewer compet studi
larg patient pool aslan therefor look region china
japan south korea southeast asia drive varlitinib rapid effici
clinic trial enrol develop still retain potenti
approv major market world-wide varlitinib current trial includ
potenti singl pivot studi condit
differ geograph region sever import near-term data
aslan
manag experi region compani plan leverag
intern presenc broad experi asia materi knowledg
interest deep
diseas
local relationship expedit drug
manag collect total year
china though expect
outlicens varlitinib eu possibl japan given manag
materi previou commerci experi asia china specif aslan
plan begin build target commerci organ china
asian market anticip potenti regulatori approv
varlitinib biliari tract cancer gastric cancer plan similar target
commerci effort varlitinib us well
varlitinib background/summari aslan varlitinib also known
promis agent pivot develop
advanc metastat biliari tract cancer phase program
gastric cancer indic high unmet need
new treatment varlitinib potent oral revers small molecul pan-
inhibitor direct activ receptor
potenti expand therapeut activ varlitinib beyond
egfr select agent cancer driven combin
signal given abil inhibit downstream
growth pathway importantli varlitinib revers bind contribut
manag gi toler profil grade diarrhea less
patient treat compar favor irrevers pan-her
inhibitor nerlynx neratinib puma biotechnolog rate
earli phase clinic studi suggest varlitinib appear gener well-
toler singl agent combin chemotherapi
standard care
varlitinib evalu patient monotherapi
combin multipl cytotox agent demonstr activ
biliari tract gastric breast colorect cancer registration-en
trial china biliari tract cancer data regulatori
file shortli thereaft region global pivot treetopp studi
line biliari tract cancer expect readout could support
potenti us approv addit gastric cancer phase
program advanc well phase data molecul fda
orphan drug design gastric cancer cholangiocarcinoma
potenti broad-bas activ underpin peak varlitinib revenu estim
excess billion exhibit
exhibit varlitinib structur activ
wallac select inhibitor erbb-famili receptor tyrosin kinas aacr annual meet
her/erbb famili receptor subfamili four close relat human
play import role
activ signal pathway cellular prolifer surviv one
receptor overexpress abnormally/mut activ
number cancersbreast lung colon stomach pancreat ovari brain
prostat kidney result receptor primarili egfr
focu robust develop target therapeut agent
chang treatment paradigm sever preval cancer type
includ breast cancer account breast
cancer egfr amplif mutat non-smal cell lung cancer
wieduwilt moasser
exhibit erbb famili growth factor receptor
her/erbb receptor tyrosin signal complex receptor famili
key signal pathway util mani tumor co-express
shown involv resist mechan select egfr
inhibitor growth factor signal member
famili complex involv wide rang activ hetero-
dimer kinas activ mani tumor type co-express multipl
her/erbb receptor ligand redund homo-and heterodim
mapk pathway cancer erbb receptor undergo
variou alter human tumor aberr erbb signal gener
associ aggress diseas poor clinic outcom tumor
activ redund erbb dimer refractori select erbb inhibitor
tumor signal though sever member famili
potenti sensit broad-act famili inhibitor
compar select egfr inhibitor
exhibit her/erbb receptor tyrosin signal complex
wallac select inhibitor erbb-famili receptor tyrosin kinas aacr annual meet
adapt sabiosci
varlitinib also oral potent revers atp-
competit select small-molecul pan-her inhibitor varlitinib
high nanomolar molecular potenc egfr
abrog downstream signal mapk pathway
varlitinib also demonstr rel balanc inhibit kinas
exhibit also demonstr activ clinic import
mutant exon delet egfr truncat
form varlitinib high select famili
inhibit kinas wallac
biolog still emerg
demonstr variou group tumor escap mechan breast
cancer cell lead acquir resist inhibitor
trastuzumab lapatinib canfield et al cell cycl gala et al clinic
cancer research therefor use pan-her inhibitor
varlitinib potenti materi benefit treatment variou
exhibit varlitinib mechan action pan inhibit
revers inhibitor varlitinib bind receptor high drug
concentr releas bind concentr lower
result varlitinib absorb gi tract transient block gut
epitheli signal pathway perman bind receptor
gut epithelium gi tracta case irrevers inhibitor
chemic bond target receptor facilit
differenti gi toxic profil support rel low
rate grade higher diarrhea broad earli clinic develop
importantli improv toxic dynam achiev parallel
sustain varlitinib concentr tumor support continu target
inhibit
left
huynh et al varlitinib demonstr potent antitumour efficaci patient-deriv gastric cancer
varlitinib show promis activ preclin model preclin
inhibit tumor growth regress sever preclin model
multipl tumor type includ egfr-express wild-typ mutant
model coexpress exhibit dual-
respons gastric carcinoma xenograft model exhibit
combin studi capecitabin docetaxel
trastuzumab
cetuximab varlitinib exhibit appear well-toler
combin drug demonstr addit super-addit activ
combin drug increas regress combin
exhibit varlitinib gastric carcinoma model pan erbb inhibit efficaci
select target
wallac select inhibitor erbb-famili receptor tyrosin kinas aacr annual meet
varlitinib activ gastric cancer pdx model single-
agent varlitinib demonstr anti-tumor activ gastric cancer patient-
deriv xenograft pdx scid mice over-express
amplif protein molecul activ
dose-depend tumor stasi observ bid regress
achiev bid varlitinib well-toler dose
minim chang mous bodyweight importantli
model show co-express drive tumor growth
varlitinib anti-tumor effect exhibit western blot analysi
show potent inhibit mapk signal pathway correl
pair biopsi data support phase trial line gastric
cancer co-express without amplif ie
varlitinib clinic
exhibit varlitinib doublet chemo activ across broad rang tumor type focu turn
varlitinib earli clinic data activ doublet chemotherapi
tract gastric colorect breast cancer
receiv varlitinib doublet chemo either
cisplatin/capecitabin folfox xelox cycl varlitinib
monotherapi progress patient least prior line therapi
enrol enrich biomark analysi shown
diseas control rate orr rate notabl tumor reduct
cholangiocarcinoma exhibit specif orr
biliari tract gastric colorect cancer
respons breast cancer studi patient across biliari
tract gastric colorect achiev prolong pr stabl diseas
week safeti profil consist receptor inhibitor
preliminari data patient enrol present
exhibit varlitinib materi activ biliari tract cancer patient
data varlitinib drive deep respons biliari tract cancer
phase trial enrol biliari tract cancer patient prior
treatment discuss break-out phase data receiv
varlitinib combin platinum plu fluoropyrimidin chemotherapi
week varlitinib monotherapi given rel high presenc
express biliari tract tumor enrol studi
select express patient patient achiev
pr tumor reduct addit
patient stabl diseas control rate exhibit
respond durat respons week impli tumor
growth control varlitinib monotherapi though respons may
seem modest respons rate expect line patient standard-of-
care chemo capecitabin modest creat reason
potenti varlitinib success line biliari tract set
exhibit varlitinib gastric cancer -- modul downstream signal pathway co-express
et al phase iia studi evalu biolog activ co-express amplifi gastric cancer abstract
pakt
immunohistochemistri assess
data varlitinib inhibit import downstream signal gastric
cancer phase pair biopsi trial conduct seoul nation
univers hospit enrol patient relaps metastat gastric
carcinoma amplifi tumor tumor co-express
tumor biopsi taken day varlitinib bid
monotherapi analyz
modul downstream signal pathway data present
esmo show among evalu pharmacodynam
popul co-express reduct pmapk activ
cell prolifer regul cellular marker
prolifer upregul tunel measur cell apoptosi
survival/proliferation/growth effect varlitinib materi impact
downstream signal pathway suggest import pan-her activ
varlitinib activ trastuzumab-refractori breast cancer
patient metastat breast cancer fail prior trastuzumab
random capecitabin plu varlitinib bid
lapatinib qd primari endpoint percentag chang
tumor reduct week tumor size reduct numer greater
varlitinib vs one-sid exhibit left
though orr similar vs patient varlitinib
evalu due incomplet first cycl treatment patient
remain studi day sensit analysi
demonstr statist signific higher reduct tumor size
varlitinib vs one-sid numer superior orr
vs exhibit right data present esmo
exhibit varlitinib achiev encourag activ vs lapatinib trastuzumab-refractori mbc
al multicent open label random phase trial varlitinib versu lapatinib combin capecitabin patient
varlitinib appear gener manag common ae
varlitinib arm diarrhea grade appear
adequ control standard dose loperamid imodium
prophylaxi consid common event lapatinib arm
diarrhea
grade palmar-plantar
erythrodysaesthesia syndrom hand-foot syndrom grade
intend exposur percentag intend dose lower
varlitinib consid profil manag compar pan
inhibitor patient studi six patient withdrew consent within
first day one patient experienc grade seriou advers
event diarrhea assess drug-rel
exhibit -- varlitinib vet chemo combo
varlitinib thoroughli explor varlitinib
bid establish monotherapi combin singlet
doublet chemotherapi regimen frequent consid biliari tract
gastric metastat breast colorect cancer upcom
aslan present full data describ varlitinib bid day
on/off use combin paclitaxel typic use part
neoadjuv therapi breast cancer broad understand
varlitinib toxic profil combin cytotox agent may afford
physician flexibl consid varlitinib variou set cancer known
express receptor view
varlitinib appear manag gi toxic note
across varlitinib clinic trial decemb rate grade
diarrhea overal compar favor
grade diarrhea event report nerlynx neratinib extenet trial
report fda label view common drug-rel
fatigu grade nausea grade
one patient die due liver failur lead multi-organ failur sepsi
day treatment varlitinib capecitabin
determin possibl relat varlitinib across trial two
death note possibl relat varlitinib includ one
relat diseas progress worsen metastat breast cancer
anoth relat acut kidney injuri
varlitinib biliari tract cancer
biliari tract cancer background/summari biliari tract cancer rare
western hemispher estim patient diagnos us
rate asia-pacif region materi higher
accord aslan diseas effect biliari system
respons transport bile fluid help break fat
liver gallbladd small intestin biliari tract cancer consist intra-
hepat extra-hepat cholangiocarcinoma cancer bile duct
repres case accord aslan cancer gall bladder
papilla vater carcinoma screen test biliari cancer
present often non-specificsuch pain metastasi
jaundic bile duct becom blockedmost patient diagnos
progress non-resect diseas diagnosi
gener made
follow blood work liver function test ct scan system
accord dana-farb cancer institut
famili express materi biliari tract cancer specif
pathway drive biliari cancer fulli elucid date recent
data japan china discuss aslan suggest biliari tract
cancer tumor famili over-express wide
express accord aslan work support system review
co-express biliari tract malign galdi et al
show co-express rang biliari cancer
overexpress report cholangiocarcinoma
materi presenc aslan enrol all-com varlitinib
select famili express line set
exhibit overview biliari tract cancer
gemcitabine/oth platinum-bas chemo
vall et al new horizon precis medicin biliari tract cancer cancer discoveri
biliari tract cancer materi unmet need target agent
approv biliari tract cancer potenti cur treatment
option surgic resect complic aggress
diseas late-stag diagnosi result patient diagnos
non-resect diseas lamarca et al howev surgic resect
limit associ high rate recurr
surviv rate intrahepat cholangiocarcinoma well
poor outcom subtyp miyazaki et al major biliari
tract cancer patient elig surgic resect
surviv rate stage stage iv diseas lamarca et al
chemotherapi doublet
primarili use line set base phase work vall et al abc-
trial nejm demonstr doublet regimen achiev os
month month orr patient progress
lack consensu regard clinic util appropri
chemo regimen set fornaro et al retrospect
analysi lamarca annal oncolog line advanc biliari
cancer studi median os month month
varlitinib on-going trial biliari tract cancer
treetopp global pivot studi biliari tract cancer data
global pivot effort line therapi biliari tract cancer aslan
enrol patient phase treetopp studi agreement fda
treetopp enrol least patient us site includ md
anderson cancer center dr milind javl lead trial total
approxim patient unselect express global site
random onto double-blind placebo-control trial evalu
varlitinib plu capecitabin co-primari endpoint orr
plan allow primari success either endpoint signific one-sid
level endpoint signific one-sid level
either co-primari endpoint reach signific aslan plan
file acceler approv us secondari endpoint includ os
durat respons diseas control rate tumor shrinkag week
top-line data expect primari complet januari per
clinicaltri gov access may could support us launch
earli
exhibit treetopp pivot studi design biliari tract cancer
treetopp benchmark success systemat review line chemo
consider success treetopp come systemat literatur
review studi evalu line chemotherapi advanc biliari
tract cancer lamarca et al drug approv
set analysi patient mean month ci
orr ci believ serv
appropri proxi
treetopp control arm addit
consider lamarca system review includ mean os
month diseas control rate previous report orr
varlitinib phase trial biliari tract cancer patient
replic treetopp support posit studi outcom view
anticip favor result file later year
potenti acceler approv us confirmatori trial would
need conduct indic full approv
exhibit single-arm pivot biliari tract cancer studi china
pivot data upcom late line biliari tract cancer
china follow posit discuss china fda aslan could file
approv line biliari tract cancer china base success meet
primari endpoint single-arm pivot trial current well
underway exhibit orr seen earli trial like enough
requir demonstr statist signific trial
report capecitabin set varlitinib data avail
late studi enrol patient progress prior
chemotherapi varlitinib plu capecitabin primari endpoint orr
secondari endpoint os studi led professor shukui
qin chair chines societi clinic oncolog deputi director
peopl liber armi pla hospit nanj director
cancer center chines pla believ studi potenti lead
approv china possibl earli late
varlitinib biliari tract cancer interim phase data
aslan enrol phase trial varlitinib plu gemcitabine/cisplatin
line biliari tract cancer patient dose-escal phase portion
determin provid basi expans plan phase
placebo-control studi gem/ci /- varlitinib patient per arm
assess primari endpoint measur independ central review
per recist propos phase studi design detect minimum
differ week assum orr chemotherapi
arm like secondari endpoint orr diseas control rate durat
respons os phase trial expect support
registr set interim data phase studi
expect benchmark current line gemcitabine/cisplatin
standard care report trial vall et al nejm
median os month vs gemcitabin
alon orr doublet gemcitabin
varlitinib opportunity/econom biliari tract cancer aslan
seek approv varlitinib treatment line biliari tract cancer
near-term note approv target therapi
minim activ seen chemotherapi regimen current
estim price approxim per month therapi varlitinib
biliari tract cancer modest price increas per year initi
approv sought varlitinib line biliari tract cancer
note previous modest perform standard care
give varlitinib uniqu broad activ broad express
tumor reason probabl success
us estim patient diagnos biliari tract
cancer elig varlitinib line
current estim price approxim per month therapi
averag time drug month averag per patient
us estim acceler approv treetopp trial
complet us estim peak util patient
revenu exceed million set china estim
target line case annual assum price per
month averag per patient estim peak util china
patient sale nearli million estim acceler
approv china late singl arm varlitinib trial complet
though biliari tract cancer preval may greater china take
cautiou view regard adopt trajectori uptak may
limit cash pay market initi reimburs establish
market primarili eu japan estim combin target
popul patient varlitinib therapi estim
acceler approv treetopp trial complet
averag price per patient eu japan similar peak
util roughli patient estim peak revenu
year outsid japan assum modest declin global
estim util varlitinib line biliari tract cancer
million peak exhibit
npv calculations/consider biliari tract cancer collect given
consider well expect varlitinib use well mid-
along patent term extens late estim
varlitinib peak revenu biliari tract cancer million
reason effici market molecul us china spread
across multipl indic assum licens varlitinib major
market approxim royalti array discount
probabl approv given well-vet biolog famili
inhibit repres demonstr activ varlitinib
molecul estim fulli tax risk-weight npv
exhibit varlitinib global market model biliari tract cancer
us biliari tract market biliari tract case w/ unresect undergo surgic respond doublet biliari tract biliari treated- averag month month tx d- price per month- price estim revenue- china biliari tract market biliari tract popul biliari treated- averag month month tx d- price per month- price estim revenue- eu biliari tract market biliari tract popul biliari treated- averag month month tx d- price per month- price estim revenue- japan biliari tract market biliari tract popul biliari treated- averag month month tx d- price per month- price estim revenue- total biliari tract use us
exhibit varlitinib npv calcul aslan biliari tract cancer display
 biliari tract total revenu expens cog us royalti cog total net rate tax effect total per valu npv/share biliari tract total revenu aslan expens cog china royalti cog total net rate tax effect total per valu npv/share biliari tract royalti royalty- upfront/mileston mileston total revenu aslan expens payment array- royalti sg a- total net rate tax effect total per valu npv/share
varlitinib gastric stomach cancer
gastric cancer background/summari gastric stomach cancer
orphan diseas us estim patient us
diagnos estimate case accord nci seer much
prevent asia-pacif region million diagnos
accord aslan diseas preval male
femal american cancer societi occur cancer cell form
stomach line typic begin mucos layer innermost layer
progress outer layer line nearbi distant
lymph node tissu and/or organ earli symptom gastric cancer includ
indigest stomach pain heartburn loss appetit diseas
progress symptom includ blood stool vomit
weight loss ascit collect fluid abdomen diseas
treatment prognosi depend stage diagnosi includ
gastrectomi remov part whole stomach surgeri
chemotherapi and/or radiat accord aacr foundat
earli symptom rel innocu non-specif gastric cancer
patient elig surgeri cur intent heemskerk et al
though recurr rel frequent us american
cancer societi estim overal surviv rate gastric cancer
us
exhibit varlitinib target opportun line gastric cancer
varlitinib co-express gastric cancer
materi opportun improv gastric cancer standard work
conduct aslan collabor institut south korea japan
suggest gastric cancer tumor co-express base
epidemiolog analysi archiv tumor target drug develop
advanc variou cancer past decad like
attribut heterogen diseas carri variou genet
mutat lack biomarker-driven patient select oh
herceptin approv target agent line gastric cancer
indic
howev use limit gastric cancer
gunturu et al addit herceptin
cisplatin/capecitabin doublet chemotherapi extend
median os month chemo standard care
varlitinib gastric cancer line consider co-express
decis expand phase aslan enrol first patient onto
phase program varlitinib line treatment advanc
metastat gastric cancer trial employ enrich design
patient co-express defin egfr
express without overexpress would
elig herceptin therapi dose folfox /- varlitinib bid
exhibit phase portion enrol patient site asia
europ assess primari endpoint chang target tumor size week
top line phase data expect posit one-sid
aslan enrol phase program addit patient assess
os base month enrol month complet os follow-up
model nda file us approv line gastric use
exhibit varlitnib line gastric cancer trial co-express
benchmark varlitinib success gastric cancer consider
herceptin subset consider success come
benefit observ ad herceptin chemotherapi gastric
cancer overexpress gunturu et al specif
addit herceptin yield orr vs chemotherapi
benefit vs month month benefit
ad less month os vs report
phase toga studi chemotherapi /- herceptin bang et al
would view similar orr benefit approach os benefit
month support varlitinib approv commerci adopt
set anticip success trial varlitinib
varlitinib opportunity/econom gastric cancer aslan seek
approv varlitinib treatment line gastric cancer patient
co-express note approv target therapi
minim activ seen chemotherapi regimen us
estim patient diagnos gastric cancer
elig varlitinib inelig surgeri
surgeri relaps current estim price
approxim per month varlitinib therapi us averag
time drug month averag per patient us
us estim peak util patient gener revenu
exceed million set china approxim
target case annual base co-express estim
patient access assum price per month averag per
patient estim peak util china patient
sale million though gastric cancer preval may
greater china take cautiou view regard price adopt
trajectori uptak may materi
initi
reimburs establish market primarili eu japan
estim combin target popul patient
varlitinib therapi averag price per patient eu
japan similar peak util roughli patient estim
peak revenu market approach million larg assum
modest price increas per year outsid japan assum step-
wise declin global estim util varlitinib line
gastric cancer co-express million
npv calculations/consider gastric cancer collect given
consider well expect varlitinib use patent mid-
plu anticip patent term extens potenti estim
varlitinib peak revenu gastric cancer million
discount probabl approv given well-vet biolog
famili inhibit repres enrich trial design reason
effici market molecul us china spread across
multipl indic licens varlitinib major market
approxim royalti back array demonstr activ
varlitinib molecul estim fulli tax risk-weight npv
exhibit varlitinib global market model gastric cancer
us gastric cancer market new gastric surgeri w/ cur w/ surgery/no avail gastric treated- averag month month tx d- price per price estim revenue- china gastric cancer market target gastric cancer gastric treated- averag month month tx d- price per month- price china revenue- eu gastric cancer market target gastric cancer gastric treated- averag month month tx d- price per month- price estim revenue- japan gastric cancer market target gastric cancer gastric treated- averag month month tx d- price per month- price estim revenue- total gastric use us
exhibit varlitinib npv calcul aslan gastric cancer display
 gastric total revenu expens cog us royalti cog sg a- total net rate tax effect total per valu npv/share gastric total revenu aslan expens cog china royalti cog sg a- total net rate tax effect total per valu npv/share gastric royalti royalty- upfront/mileston mileston total revenu aslan expens payment array- royalti sg a- total net rate tax effect total per valu npv/share
singapor enrol phase single-arm investig sponsor studi
varlitinib patient progress line nexavar sorafenib
lenvima lenvatinib dose-escal portion determin maximum
toler dose efficaci assess cohort
estim primari complet accord clinicaltri gov
metastat breast cancer standard treatment metastat
breast cancer includ combin trastuzumab pertuzumab
taxan line treatment line treatment line
set clinician administ therapi combin t-
previous administ patient previous receiv
defin standard treatment patient popul
pan-her agent use set associ toxic
agent late-stag develop though
probabl weight possibl breast cancer use varlitinib
valu modest right assum revenu use
set model
exhibit molecular pathway biliari tract cancer
vall et al new horizon precis medicin biliari tract cancer cancer discoveri
oh novel system therapi advanc gastric cancer journal gastric cancer
gilotrif afatinib boehring ingelheim oral irrevers egfr
inhibitor develop across phase trial gastric
gastroesophag junction gej cancer show tumor reduct
gastric cancer pdx model drug initi approv
fda approv first-lin egfr nsclc popul
squamou cell carcinoma lung follow platinum-bas chemotherapi
grade rate diarrhea report nsclc clinic trial includ
fda product label rang drug evalu
phase trial unselect line non-resect gastric/gej
cancer combin single-arm studi enrol
patient assess orr primari endpoint potenti data mid-
anoth single-arm phase trial enrol
line gastric/gej cancer patient egfr express
gilotrif plu paclitaxel primari endpoint orr data could
avail around yearend studi enrol
trastuzumab-refractori esophagogastr cancer patient
gilotrif plu paclitaxel trial assess primari
endpoint orr data potenti
puma biotechnolog nerlynx neratinib nerlynx neratinib puma
inhibitor approv fda juli extend adjuv
treatment adult earli stage breast
cancer adjuv trastuzumab-bas therapi base larg result
patient extenet phase studi neratinib versu placebo
adjuv treatment trastuzumab earli stage breast
cancer compound also investig treatment
metastat metastat brain metastas neoadjuv mutant
posit breast cancer exhibit neratinib potent inhibit egfr
lesser degre
exhibit neratinib examin breast cancer set
extenet two-year follow-up neratinib result reduct
risk invas diseas recurr death versu placebo hazard ratio
endpoint neratinib arm placebo arm
pre-defin subgroup patient hr posit diseas neratinib use
result reduct risk invas diseas recurr death
exhibit neratinib high rate sever diarrhea seen across studi
confer efficaci breast cancer patient also carri challeng
toxic well frequent observ advers event
neratinib-tr patient extenet trial diarrhea
neratinib-tr patient experienc grade higher diarrhea patient
grade diarrhea treatment prophylact loperamid reduc
rate grade higher diarrhea metastat breast cancer
frequenc diarrhea
publish trial without
chemotherapi exhibit shown onset sever
diarrhea commonli occur first month treatment trial use
loperamid prophylaxi shown reduct rate grade diarrhea
trial neratinib monotherapi varlitinib appear
suffer sever diarrhea neratinib
spectrum poziotinib poziotinib novel oral quinazoline-bas pan-her
inhibitor irrevers block signal famili tyrosine-
kinas receptor includ well
receptor mutat current phase ii develop march
spectrum rate enter licens agreement hanmi
develop manufactur
commerci poziotinib world-wide indic exclud korea
china hanmi current investig poziotinib differ solid tumor
indic includ breast lung gastric cancer
poziotinib target patient fail therapi poziotinib
shown solid respons rate clinic benefit rate cbr
mpf week phase patient breast cancer previous
fail multipl line treatment includ therapi
median durat respons week rang week given
lack select frequent report grade ae expect
diarrhea phase studi anti-diarrh medicin allow
prophylact anti-diarrh therapi use spectrum initi
phase ii breast cancer program februari primari
complet date decemb base phase efficaci data
breast cancer patient us phase trial open-label studi
enrol approxim patient metastat breast cancer
fail least two prior therapi knowledg
poziotinib examin combin breast cancer
treatment brain met patient
manag current focus develop poziotinib lung cancer
recent present spectrum manag state breast
cancer program on-going excit develop poziotinib
lung cancer patient exon insert mutat manag
describ lung cancer program eureka moment compani
oh novel system therapi advanc gastric cancer journal gastric cancer
promis oral dhodh inhibitor aml
summari oral avail potent
inhibitor dihydroorot dehydrogenas dhodh potenti
first-in-class agent acut myeloid leukemia aml shown
potenti induc blast cell differenti major aml cell
exhibit potent preclin activ roughli order
magnitud greater first-gener dhodh inhibitor improv
pk/pd profil allow full exposur achiev hour
half-lif eas toxic concern associ earlier
dhodh inhibitor aslan investig util phase
trial relapsed/refractori acut myeloid leukemia aml interim data
expect addit preclin effort explor use solid
tumor includ triple-neg breast cancer tnbc hepatocellular
exhibit dhodh inhibitor mechan action
dhodh background dhodh ubiquit metabol enzym locat
inner mitochondria membran control rate-limit step de
novo pyrimidin synthesi essenti build block dna rna
also play role product adenosin triphosph atp
increas level support tumor growth surviv cancer
specif dhodh catalyz convers dho orotateth step
pyrimidin synthesi transfer enzym dho complex
electron-transport chain syke et al enzym known
mutat overexpress cancer syke et al inhibit
enzym shown trigger activ tumor suppressor
inhibitor approv autoimmun
indic aubagio teriflumid approv treatment relaps
form multipl sclerosi prodrug arava leflunomid approv
treat activ moderate-to-sever rheumatoid arthriti psoriat arthriti
molecul suffici dhodh inhibitor slow inflammatori
cell prolifer use chronic set materi
potent dhodh inhibitor demonstr exhibit may enabl
success develop oncolog indic molecul
attempt first-gener inhibitor unsuccess addit first-
gener dhodh molecul design higher dhodh potenc
associ unaccept toxic result off-target bind
materi drug accumul could requir year clear
pharmacolog activ level importantli chemic
relat first-gener dhodh inhibitor
potent gener dhodh inhibitor
overwhelm benefit all-tran
dhodh inhibit potenti role aml therapi goal aml
therapi overcom myeloid cell differenti blockad demonstr
differenti agent achiev cure rate small acut
syke et al cell recent publish work describ inhibit
dhodh enzym facilit myeloid differenti human mous aml
cell find base observ gene
downregul normal myeloid differenti express
major aml cell uncommon find given heterogen
malign
exhibit dhodh inhibit improv surviv primari leukemia left
lower leukemia-initi cell right secondari transplant mice
syke et al inhibit dihydroorot dehydrogenas overcom differenti blockad acut
use high throughput screen author identifi dhodh enzym
target activ compound downregul
hit librari compound find
support vitro vivo studi aml model show
dhodh inhibitor spark myeloid differenti result deplet
function leukemia-initi cell mechan dhodh-induc
myeloid differenti isnt fulli understand author postul
effect like involv combin inhibit nucleic acid synthesi
cell-cycl arrest chang post-transl glycosyl
data enabl differenti aml cell line dose
drove differenti human aml blast cell line
specif cell expos compound concentr
equival qd dose upregul cell
surfac marker normal immun cell exhibit left suggest
differenti aml blast granulocyt type white blood cell
drug exposur led format hallmark consist
normal human granulocyt activ granul cytoplasm
demonstr reduct nitro tetrazolium nbt
standard assay granulocyt exhibit right
exhibit activ aml cell line unrespons
improv pharmacokinet profil phase singl
multipl ascend dose studi conduct healthi
caucasian asian subject pk dose-proport
importantli accumul bodi issu
gener dhodh inhibitor singl dose drug exposur similar
race exhibit left stabil multipl dose exhibit
exhibit pharmacokinet support use oncolog set
state exposur qd achiev dhodh
inhibit exhibit green compar favor inhibit
maximum dost teriflunomid exhibit red accord aslan
interim phase aml data phase studi initi
enrol relapsed/refractori aml patient site singapor
australia assess monotherapi
dose day progress primari endpoint
rate complet remiss complet remiss incomplet
bone marrow recoveri interim data dose-rang monotherapi
portion could support move expand patient cohort
allow combin standard induct chemotherapi
data could provid basi discuss potenti pathway
acceler approv fda
exhibit activ aml cell line unrespons
emerg competit appear advanc
effort underway industri player activ pursu
dhodh target includ bayer bayri rate
current enrol phase dose-escal trial patient
advanc myeloid malign greater line therapi agio
rate late-stag preclin develop
dhodh inhibitor may day project ind
file dhodh interim phase readout
upcom appear advanc program
summary/background compani preclin
potenti first- class fulli human monoclon antibodi target il-
receptor subunit inhibit signal
key cytokin trigger symptom allergi atop dermat red
itch well asthma symptom short breath wheez
cough aslan intend file ind begin clinic
develop molecul sever atop dermat asthma
posit proof concept hand aslan seek partner phase
commerci program licens limit
receiv econom
exhibit receptor antibodi mechan action
potenti advantag
narrow cellular distribut subunit target
regeneron pharmaceut neutral analyst dane leon
sanofi sni rate dupix dupilumab potenti allow
dose lower volum frequenc dupix
dose everi week addit target
subunit receptor block type
receptor contrast dupix dose present cell
macrophag avoid type receptor may improv safeti profil
partner bristol-my squibb
aslan enter licens agreement bristol-my squibb
exclus right develop commerci
china australia korea taiwan select asian countri without
up-front payment bristol retain exclus right rest
world agreement aslan would fund develop
proof concept develop plan would initi target
gastric cancer lung cancer aslan complet phase clinic
trial bristol licens exclus right aslan continu global
develop commerci aslan receiv
up-front payment million could receiv addit
develop regulatori mileston million
advanc well undisclos royalti payment estim
ron agreement exploit technolog ltd
laboratori august agreement provid aslan licens
intellectu properti develop research collabor etpl
laboratori center develop novel antibodi target recepteur
dorigin nantai ron immune-oncolog use agreement call
laboratori conduct preclin develop asset
aslan respons clinic develop plan etpl elig
million mileston undisclos royalti net sale
modybodi agreement nanyang technolog univers ntu
aslan ntu enter research collabor licens agreement
octob develop modybodi aslan-nomin target
aslan pre-negoti exclus option licens global right
develop commerci modybodi select target
exercis option aslan ntu up-front million
mileston tier single-digit royalti net sale aslan
exercis option
aslan gain exclus global right develop manufactur
commerci varlitinib human anim therapeut diagnost
prophylact use goal fda approv us commerci
aslan paid million up-front pay addit million
later januari potenti mileston array includ million
develop million regulatori million commerci
event aslan also pay tier royalti low ten net sale
last patent claim year first commerci sale
countri countri addit aslan sublicens varlitinib anytim
januari array receiv up-front payment receiv
aslan undisclos amount sublicens royalti less
array receiv amount actual receiv aslan
array also receiv low mid-singl digit percent proce chang
control scenario aslan agreement replac earli agreement
enter juli requir aslan partner varlitinib follow clinic
proof concept gastric cancer
varlitinib hyundai pharm co commerci varlitinib south korea
aslan enter licens agreement octob hyundai pharma
wherebi hyundai receiv option acquir right commerci
varlitinib treatment cholangiocarcinoma south korea aslan
elig receiv regulatori commerci mileston royalti
enter global licens agreement almiral may develop
initi treatment prevent
rheumatoid arthriti agreement amend decemb
march expand scope includ exclus world-wide licens
develop manufactur commerci product human
diseas primari focu oncolog except topically-
administ product non-melanoma skin cancer aslan gener
right sublicens consider amend aslan pay
almiral million develop million regulatori
mileston almiral receiv tier royalti mid-single-digit rang
net sale sublicens revenu earn aslan
enter global licens agreement limit may develop
monoclon antibodi antigen bind
fragment thereof treatment diagnosi prevent diseas
condit human up-front payment aslan fund
develop clinic proof-of-concept patient moder
persist sever allerg asthma refractori exist therapi
asian-focus develop program aslan right grant
commerci right third-parti upon establish clinic proof-of-concept
right commerci independ
aslan requir pay licens revenu receiv
array relat patent varlitinib composit matter patent deriv
patent famili licens array
schedul normal expir potenti extens
decemb issu patent famili us least
relat intermedi process europ japan china
least hong kong south korea singapor other
first patent applic file varlitinib china grant base
technic chines practic subsequ file division patent
applic grant valid one grant
division patent challeng one patent may
ultim consid invalid china typic brand medicin may still
grow market share even patent expir trend along
subsequ file patent applic chines data exclus
provis may minim impact neg decis may
receiv respect one division patent varlitinib
addit ip file includ combin chemotherapi
file china europ japan korea singapor us pend
applic earliest prioriti date septemb file
date septemb normal expiri septemb
synthet process manufactur varlitinib certain key
intermedi expect protect patent famili deriv
schedul expir normal
potenti extens decemb issu patent
famili us europ japan china hong kong south korea
singapor taiwan other
aslan patent part aslan clinic develop effort
continu file new intellectu properti extend varlitinib exclus
period publish applic princip relat
use
combin therapi patent grant normal exclus
period would run accord aslan addit aslan
one unpublish pct applic least unpublish singapor
publish pct applic file septemb
claim use varlitinib sensit cancer patient
chemotherapi ie use varlitinib combin chemotherapi
applic file us china europ japan korea singapor
addit publish pct applic relat varlitinib use certain
patient popul file septemb relat
treatment biliari tract cancer file septemb
cover use treatment resist cancer file april
treatment
could opportun explor reformul ip part life cycl
almiral relat patent composit matter famili
patent exclus licens almiral deriv
expir decemb without extens decemb
composit matter patent issu us patent europ
japan china hong kong other
applic claim certain specif use
relat patent composit matter patent famili
deriv exclus licens schedul
expir without extens decemb patent
issu unit state patent europ patent japan patent
china other
joint patent aslan joint owner one unpublish singapor
prioriti patent claim specif therapeut use
continu joint intellectu properti opportun like includ
manufactur formul accord aslan
aslan continu util third-parti group manufactur
product candid us europ asia
varlitinib aslan contract two cgmp-compliant cmo base
uk china develop valid commerci manufactur process
varlitinib initi commerci suppli batch expect
avail late uk-bas sterl pharma solut limit
manufactur varlitinib drug substanc accord cgmp scale
current process valid scale varlitinib drug product
produc pci pharma servic uk manag believ drug
substanc product scale ton per annum aslan
establish second cgmp manufactur site wuxi apptec china
produc drug substanc product wuxi success manufactur
scale
 drug substanc produc accord
cgmp sigma-aldrich compani switzerland scale drug product
produc capsul form accord cgmp wuxi china
aslan expect tablet formul addit
scale-up optim effort
 selexi sa base switzerland creat manufactur cell line
yield drug substanc per liter
jhl biotech establish process develop complet
manufactur support toxicolog cgmp clinic suppli aslan
current work
identifi long-term commerci manufactur
vetter pharma intern gmbh us respons
cgmp fill finish effort clinic trial
carl firth ph founder chief execut offic dr carl firth
found aslan serv chairman sinc june
ceo sinc januari director sinc juli immedi prior
dr firth head asia healthcar america merril lynch
rate led public privat financ effort advis
 transact previous dr firth employ
astrazeneca multipl commerci role
includ region busi develop director asia pacif director
new product develop china dr firth member
singapor biomed scienc intern advisori council
sinc septemb independ director singapor exploit
technolog commerci arm sinc april
also serv adjunct professor duke-nu medic school sinc
independ director hong kong exchange-list chines
biopharmaceut compani uni-bio scienc novemb
receiv ph molecular biolog cambridg univers triniti
colleg execut london busi school
molecular biolog cambridg univers
bertil lindmark ph chief medic offic dr lindmark
serv chief medic offic aslan sinc join compani march
came aslan almiral sa execut
director research develop board
earlier dr lindmark spent approxim year astrazeneca
vice presid led global clinic develop effort respiratori
inflamm spent year vice presid head clinic
develop astrazeneca japan receiv ph
molecular biolog univers lund specialist qualif
intern medicin gastroenterolog
mark mchale ph chief oper offic dr mchale help found
aslan serv sinc februari join aslan
astrazeneca head molecular scienc respiratori
inflamm busi respons new
target identif asthma earlier spent year smithklin
beecham gsk rate support lead optim effort serotonin
dopamin receptor dr mchale earn ph molecular biolog
univers east anglia uk genet
molecular biolog univers london
jeff tomlinson chief busi offic mr tomlinson play role
found aslan serv chief busi offic sinc januari
brought aslan experi sever senior busi
develop role activ pass pharmaceut pharmacopai bioscienc
genelog well learn time ventur capit
investig
industri earlier mr tomlinson princip
manag technic sale receiv
univers western ontario
goodger gener counsel mr goodger join aslan novemb
prior role head intellectu properti licens
transact osborn clark join novemb
previous octob mr goodger head
intellectu properti commerci edward wildman uk
execut head intellectu properti commerci
rous co mr goodger earn english literatur
languag oxford univers exhibition kebl colleg
us uk within
kiran asarpota vice presid financ mr asarpota serv vice
presid financ sinc join aslan novemb previous
group financ director global brand group hold limit
rate year respons group corpor
commerci financ function receiv london south
bank univers uk oxford brook
stephen doyl vice presid commerci head china mr doyl
join aslan februari prior role vice presid head
specialti china boehring ingelheim februari
prior boehring spent year variou role sanofi sni
includ vice presid oncolog hematolog
transplant busi shanghai region commerci director
oncolog asia pacif russia india director head
receiv clinic pharmaci univers derbi
pharmaci robert gordon univers uk
regulatory/fda compani whose main busi
drug
develop aslan subject rigor development regulatori
requir us food drug administr fda
intern regulatori agenc cfda china pmda
japan new drug approv maintain statu promot
approv drug also strictli regul fda relat agenc
throughout globe also gener though compani specif focu
ethic prescript pharmaceut place signific risk oper
due oversight fda government regulatori bodi
believ specif risk time greater
research-bas drug develop compani asln share materi
depend clinic success varlitinib lesser extent
dhodh inhibitor preclin pipelin aslan fail obtain licensur
molecul compani like experi extrem challeng
circumst gener meaning revenu profit
manufactur risk fda recent quit vigil regard
inspect drug manufactur plant aslan could subject addit
risk type fda regard manufactur varlitinib
program submit licensur us
approv
meaning problem aslan
manufactur oper contract accomplish goal
issu could materi asln share
commerci risk commerci infrastructur necessari penetr
hospit market varlitinib lesser extent appear
meaning hospit drug formulari accept often quit challeng
execut
consider experi asian drug develop clinic trial execut
aslan organ experi market drug
current sale forc materi commerci risk adopt
product exist compani unabl achiev signific product sale
necessari profit asln share could materi harm also
aslan attempt engag fail obtain commerci partner either
intern us market asln share potenti
payer may find valu proposit varlitinib accept insur
compani could requir rigor requir prior author
payment varlitinib payer significantli accept varlitinib
product demand could insuffici obtain profit materi
neg affect aslan busi moreov insur compani adopt
oner requir varlitinib demand product could
materi neg affect could also hinder profit
neg affect aslan revenu profit potenti
proce million recent us ipo fund oper
multipl upcom catalyst compani fail obtain
necessari cash complet full develop varlitinib
global hire sale forc us geographi
asln share could substanti harm addit potenti dilut
may inhibit potenti materi asln share advanc
exist may off-put potenti investor asln share
oncolog develop current develop
environ oncolog therapeut gener favor
guarante current develop climat remain place new
old challeng aris despit best effort aslan manag
team asln share potenti produc neg return holder
risk price asln may limit trade price
ordinari share tpex list tpex sinc june
code tpex set certain limit trade
volatil ordinari share current limit daili price
movement tpex result limit potenti increas
trade price adss may purchas may materi limit
base perceiv valu ordinari share tpex similarli
decreas trade price ordinari share tpex due
percept investor market may impact valu cross list
ordinari share adss follow us ipo may advers affect
liquid valu adss also may dilut liquid
secur one market may advers affect develop
activ trade market adss us addit currenc
fluctuat new taiwan dollar dollar may
advers impact valu adss
materi risk indirect competitor vaccin antibodi
immuno-oncolog molecul tki among other could present
materi challeng market penetr varlitinib patient
progress later line might affect earlier therapi therebi
truncat varlitinib potenti varlitinib toler may ultim
materi differenti tki efficaci may suffici
distinguish potenti exist competit aslan qualifi
foreign privat issuer requir file period report financi
statement sec frequent promptli domest compani
could
addit right asln
sharehold may differ right typic offer sharehold
 corpor aslan corpor affair govern articl
law govern cayman island corpor compani engag
drug develop market sale busi well common
law cayman island certain right respons sharehold
holder member board director cayman law
differ appli us corpor fiduciari duti
director cayman island exempt compani may
fiduciari duti director corpor differ
may creat materi advers chang holder right compar
us domicil corpor materi differ
well understood potenti owner prior purchas
statement except per product revenuevarlitinib total- us aml global rev partner us global rev us global rev partner us other/collab proprietari drug revenu mileston royalti revenu royalti partners- up-front mileston total roylti upfnt milestn revenue- total aslan expens oper marginnmnmnmnmnmnmnmnmnm interest interest incom financ incom incom pre-tax marginnmnmnmnmnmnmnmnmnmeffect tax tax tax incom loss effect fulli marginnmnmnmnmnmnmnmnmnmoth comprehens incom loss comprehens incom ex-charg eff ex-charg comprehens incom eff o/ o/ share ordinari expens sale -- year year growth ex-charg limit sec document btig estim contact inform robert bert hazlett manag director btig research
balanc sheet investments/mktb account prepaid current current properti equip intang refund total trade long-term debt liabil current long-term equiti ordinari capit accumul comprehens accumul equiti sharehold total liabil sharehold statement oper activitiesnet incom depreci stock-bas financ fx expens current oper oper invest activ capit expenditur payment intang matur purchas invest financ activ issuanc prefer issuanc common stock proceeds/retir financ cash increas decreas end cash aslan pharmaceut limit sec document btig estim contact inform robert bert hazlett manag director btig research
btig cover compani mention report
appendix analyst certif import disclosur
